About this trial
CONSTELAR is a prospective, single-arm, multi-specialty registry designed to evaluate the safety and intraoperative performance of the RonovoTM robotic surgical platform in adult patients undergoing elective oncological surgery. The study enrolls patients across four surgical specialties (Digestive Surgery, Thoracic Surgery, Urology, and Gynecology) at a single academic center. Primary endpoints include 30-day and 90-day complication rates (Clavien-Dindo classification), operative times, conversion rates, estimated blood loss, and device-related technical failures. Secondary endpoints encompass length of hospital stay, Intensive Care Unit (ICU) admission, readmission/reoperation rates, and oncological surgical outcomes (resection margins, lymph node harvest). The study aims to provide initial safety and feasibility data to support the regulatory pathway for the RonovoTM platform in Latin America.
Eligibility criteria
Qualifiers
Age ≥ 18 years
Confirmed malignancy diagnosis
Elective indication for robotic approach using RonovoTM
Able to understand and sign informed consent
Disqualifiers
Formal contraindication to minimally invasive surgery
Severe comorbidity prohibiting the procedure
Refusal to participate or sign informed consent
Emergency surgery
Trial design
Treatments tested in this trial
- RonovoTM Robotic Surgical Platform
Treatment groups
Sponsors and collaborators
Instituto do Cancer do Estado de São Paulo
Lead sponsor
Ronovo (Shanghai) Medical Science and Technology Ltd
Collaborator